Using Transcriptomics to Study Drug-Induced Liver Injury in 3D Cellular Models
This webinar is part of the 3D Cell Biology Webinar Series.
In this webinar, we will discuss:
- Drug-induced organ toxicity and the development of novel drugs
- Use of 3D liver models with HCS and high-throughput RNA-seq to study drug-induced liver injury
- Assessing cell viability in 3D cultures with CellTiter-Glo® 3D
Summary
3D cell cultures and assays are advancing the field of predictive toxicology. In this webinar, Dr. Jim Cali will discuss how to choose the best assays for use in 3D cultures, with a focus on CellTiter-Glo® 3D as a tool to assess cell viability. Dr. Alicia Rosell-Hidalgo will present how to use high-content screening (HCS) and high-throughput RNA-seq techniques in 3D liver models to gain a mechanistic understanding of compound effects and develop novel predictive models.
Other webinars in this series:
Setting Up Easy-to-Analyze Physiologically Relevant 3D Cultures for in vitro Studies
Ask the Experts: 3D Cell Culture and Assays
Development of 3D Liver Spheroid Cultures and Tools for 3D Culture Metabolic Studies
Speakers
Jim Cali, PhD
Director, R&D Assay Design
Promega Corporation
Dr. Cali is Director of Research for the Assay Design Department at Promega Corporation in Madison, Wisconsin. The group leverages optical chemistries to develop novel cell-based and biochemical assays. Prior to joining Promega, he was a postdoctoral fellow and then assistant professor at the Geisinger Clinic with a focus on signal transduction. He received his Ph.D. from the University of Texas Southwestern Medical Center in Dallas, Department of Molecular Genetics. His dissertation work was on the role of cytochrome P450s in heritable human disease. Dr. Cali has authored over 60 journal articles and book chapters and is an inventor for 18 issued patents.
Alicia Rosell-Hidalgo, PhD
Associate Principal Scientist in Toxicology
Cyprotex Discovery Ltd.
Dr Alicia Rosell-Hidalgo is an Associate Principal Scientist in Toxicology at Cyprotex Discovery Ltd, a subsidiary of Evotec. She leads the in vitro research and development carried out in the UK site for the “Panomics” project, aimed at improving predictive toxicology through 2D and 3D cell-based models combined with high throughput RNA-seq and machine learning/artificial intelligence techniques.
Alicia has a Bachelor of Science in Biology and master’s degree in Biochemistry at the University Complutense of Madrid. During her undergraduate years, she gained laboratory experience through collaborations with the Spanish National Research Council (CSIC) and the University of Brighton. In 2020, she was awarded a Ph.D. by the University of Sussex, where she researched drug-induced mitochondrial dysfunction.